Adult Malignant Glioma Therapeutics Market to Reach US$ 2,964.5 Mn by 2026, Exhibiting a CAGR of 9.3% | Fortune Business Insights

World News: . []

Pune, Aug. 14, 2019 (GLOBE NEWSWIRE) -- The global Adult Malignant Glioma Therapeutics Market is likely to grow in the coming years due to advancements made in targeted therapy to treat malignant glioma. According to a report published by , titled the market was valued at US$ 1,459.1 Mn. Fortune Business Insights states that the market is likely to reach US$ 2,964.5 Mn at a CAGR of 9.3% in the forecast period.

According to the World Health Organization (WHO), almost 2,45,000 brain tumor cases are registered every year. Despite advancements in treatment options and awareness regarding prevention of tumor at an early stage, the incidence of brain tumor has been on the rise. With increasing glioma cases and a low survival rate among people diagnosed with glioma, there are several market players focusing solely on the research and development of novel therapeutics to treat adult malignant glioma. The aforementioned factors are driving the global Adult Malignant Glioma Therapeutics Market.

Researchers have come up with a new imaging technique that may help in eliminating the malignant tumor from the human body, altogether. This imaging method may help surgeons locate the tumor with ease. Researchers have claimed that this technique involves the use of a synthetic version of a molecular compound found in the venom of a scorpion. The method also involves the use of an infra-red (IR) camera along with an imaging reagent tozuleristide (BLZ-100). The primary aim of this method was to determine the boundaries between a healthy tissue and tumor. This helps in retaining the healthy tissue after the surgery and thus increases the efficiency of the overall process. Such discoveries are likely to favour growth of the global Adult Malignant Glioma Therapeutics Market in the forthcoming years.

In December 2018, Blue Earth announced that it has received FDA clearance for a new drug “Axumin”, which has application in positron emission tomography (PET) imaging for removing tumors. The company announced that Fluciclovin (or Axumin) enables PET imaging that may help detect the precise location of the tumor within the body. Along with precise location, the size and severity of tumor can also be traced. This will massively help in treating the malignant glioma disorder and reduce the overall fatality rate among people diagnosed with this disorder. Thus, the FDA approval will help the company take huge strides towards their aim of developing an efficient malignant glioma treatment method. Blue Earth’s success may have impact on the global Adult Malignant Glioma Therapeutics Market and will lead to growth of the market in the coming years.

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. 

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. 

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

More news and information about Fortune Business Insights

Published By:

Globe Newswire: 13:08 GMT Wednesday 14th August 2019

Published: .

Search for other references to "adult" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us